Newborn screenings can help with a number of conditions. An investigation examines the impact of them on the outcomes of children with inherited metabolic diseases.
Over the years the push to perform extended newborn screenings have increased the number performed and helped improve outcomes for a number of children. The impact of screenings on long-term clinical outcomes among individuals who had inherited metabolic diseases is not particularly well-known. An investigation in Pediatrics examines the impact of the screens on those future outcomes.1
The investigators used a prospective multicenter observational study to look at the clinical outcomes of people with inherited metabolic diseases that were identified by newborn screening programs. There were a total of 306 people with inherited metabolic diseases who were followed for a median time of 6.2 years. There were 115 people with phenylketonuria and 191 with other inherited metabolic diseases with a lifelong risk for metabolic decompensation. The risk for metabolic decompensation was disease-specific and the screenings were not able to prevent decompensations in every person who was at risk, but the majority of the participants did not develop permanent disease-specific signs (75.9%), showed normal development (95.6%) and normal cognitive outcome (87.7%; mean IQ: 100.4), and mostly attended regular kindergarten (95.2%) and primary school (95.2%).
The results show that individuals with phenylketonuria, who served as the benchmark, as well as those with a lifelong risk of metabolic decompensation had favorable long-term outcomes and that a high newborn screening process quality was a necessity for this positive result. This belief was supported by 28 people who presented with first symptoms at a median age of 3.5 days before the screening results were available, by the absence of neonatal decompensations following the report of the screening results, and by the challenge of keep all relevant process parameters at a consistently high level.
The investigators concluded that using newborn screening is a highly successful element of secondary prevention for inherited metabolic diseases. However, the screenings may not be successful in completely preventing clinical presentation in all individuals.
Reference
1. Mütze U, Garbade S, Gramer G, et al. Long-term outcomes of individuals with metabolic diseases identified through newborn screening. Pediatrics. October 13, 2020. Epub ahead of print. doi:10.1542/peds.2020-0444
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.
Hematocrit levels in newborns: EPP vs DCC study reveals surprising findings
November 15th 2023A recent study in JAMA Network Open investigates the impact of extrauterine placental perfusion versus delayed cord clamping on hematocrit levels in newborns, shedding light on potential alternatives for optimizing infant outcomes during birth.
Preterm infant HRQOL: Long-term impacts and determinants
October 21st 2023A recent study was highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition that shed light on the long-term impact of very preterm birth on the health-related quality of life (HRQOL) of infants and identified key determinants.